LATEST ARTICLES
CORRECTION — Vaccinex to Present Additional SIGNAL Data at Huntington Study...
IGNAL Phase 2 trial data continue to support cognitive benefit and reduced brain atrophy with pepinemab treatment in Huntington’s disease
Data provide strong rationale for continued development in Huntington’s and other slowly progressive neurodegenerative diseases, including Alzheimer’s
ROCHESTER, N.Y., Oct....
Prilenia Enrolls First Patients Into its PROOF-HD Phase 3 Clinical Trial...
PROOF-HD is designed to replicate previous findings of pridopidine demonstrating maintenance of functional capacity in early Huntington’s Disease patients
Conducted in collaboration with...
Treatment for neurological disorder could be repurposed for Huntington’s disease patients
While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD....
UNIVERSITY
World first study reveals altered gut bacteria in Huntington’s Disease which...
The first clinical study of the gut microbiome in Huntington’s disease (HD) has found evidence of gut dysbiosis (altered bacteria in the gastrointestinal tract) in people...
Neural vulnerability in Huntington’s disease tied to release of mitochondrial RNA
In the first study to comprehensively track how different types of brain cells respond to the mutation that causes Huntington’s disease (HD), MIT neuroscientists...
Study reveals intricate details about Huntington’s disease protein
The research adds to a body of work devoted to understanding the protein’s role in cell biology and health
A new study reveals intricate details...
Ohio State Conducts First Gene Therapy Clinical Trial For Huntington’s Disease
COLUMBUS, Ohio – In a worldwide first, surgeons at The Ohio State University Wexner Medical Center have treated two patients with Huntington’s disease using a novel...
HDBUZZ
Treatment for neurological disorder could be repurposed for Huntington’s disease patients
While developing a drug called branaplam for patients with SMA, the pharmaceutical company Novartis discovered that it could hold promise for people with HD....
Updates from the EHDN Plenary Meeting 2020
Read our summary of the latest updates from the EHDN Plenary Meeting 2020
In September, the European Huntington’s Disease Network (EHDN) hosted a virtual webinar...
ARTICLES
IONIS-HTTRx
